TheraQuest Biosciences
Appoints Scientific Advisory Board and Launches New Corporate Website
Blue Bell, PA – August 4, 2004/PRNewswire/ – TheraQuest Biosciences,
a development stage pain management company has appointed a Scientific
Advisory Board to help guide the company's research programs
and build its pipeline of analgesics. TheraQuest also announced
the launch of its new corporate website at www.theraquestinc.com.
TheraQuest’s appointees include world-class scientists
and clinicians with an impressive track record in their respective
areas. Together with the current management team, the new Scientific
Advisory Board promises to advance further TheraQuest’s
development programs for the treatment of acute and chronic
pain.
"We believe the collective guidance from our management
team and Scientific Advisory Board will enable TheraQuest to
move forward rapidly with the development and commercialization
of our various product opportunities", said Najib Babul,
PharmD, President and Chief Executive Officer of TheraQuest.
Scientific Advisory Board Members
Richard Payne, MD,
is Immediate Past President of the American Pain Society, Professor
of Medicine and Director, End of Life Care
Institute at Duke University. Dr. Payne has published over
200 manuscripts, abstracts and book chapters. He is Chairman
of the Task Force on Pain of the American Academy of Neurology
and a member of the Board of Directors of the American Academy
of Pain Medicine and the American Pain Society.
Troels Jensen, MD, PhD, is President Elect for the International
Association for the Study of Pain and Professor of Experimental
and Clinical Pain Research, Aarhus University, Denmark. Dr. Jensen
has authored more than 175 scientific papers in peer-reviewed
journals and he is editor of three books on pain. Dr. Jensen
leads the Danish Pain Research Center at Aarhus University, Denmark.
Arthur Weaver, MD, is Past President of the American College
of Rheumatology and Clinical Professor of Medicine at the University
of Nebraska. Dr. Weaver has published over 150 manuscripts and
abstracts in rheumatology. He is a recipient of the Arthritis
Foundation Founders Award, the Mayo Clinic Philip Hench award
for excellence in rheumatology and the American College of Rheumatology
Pauldine Phelps Award.
Raymond Sinatra, MD, PhD, is Professor of Anesthesiology at Yale
University Medical School. Dr. Sinatra is Senior Editor of the
textbook Acute pain: Mechanisms and Management and has authored
over 200 scientific papers, review articles, abstracts and textbook
chapters on pain management obstetrical anesthesiology and intraoperative
anesthesiology.
Arthur Lipman, PharmD, is Professor of Pharmacotherapy, College
of Pharmacy, and Director, Clinical Pharmacology at the Pain
Management Center, University of Utah Hospitals and Clinics.
Dr. Lipman has over 300 scientific publications and abstracts.
He served on both the Acute and Cancer Pain Management Guideline
Panels of the U.S. D.H.H.S and co-chaired the Arthritis Pain
Management Clinical Guidelines Panel of the American Pain Society.
Frank Porreca, PhD, is Professor of Pharmacology, College of
Medicine, University of Arizona. Dr. Porreca is an internationally
recognized analgesic pharmacologist. He is an Associate Editor
of Life Sciences and Pain and he serves on the Editorial Boards
of a number of leading journals. Dr. Porreca has published over
250 manuscripts, 28 book chapters and hundreds of scientific
abstracts.
About TheraQuest Biosciences
TheraQuest Biosciences, LLC is a private, development-stage
pain management company building a diversified portfolio of pharmaceutical
products to address a critical area of unmet medical need. Despite
their limitations, current treatments for acute and chronic pain
yield worldwide sales in excess of $25 billion. The TheraQuest
team has contributed to the development of numerous analgesics
approved in the U.S. over the past 20 years. TheraQuest’s
strategy is to use its expertise to identify, develop and commercialize
product candidates with strong market potential that have lower
development costs and reduced regulatory risk than new chemical
entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.
Additional information about TheraQuest is available at www.theraquestinc.com.
BACK
Contact:
Najib Babul, PharmD
CEO
TheraQuest Biosciences
146 Medinah Drive
Blue Bell, PA 19422-3212
Tel: 610.272.2071
|
